In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Combination immunosuppressive therapy with prednisone and azathioprine for virus-negative inflammatory cardiomyopathy: meta-analysis of all available evidence

Session Poster Session 3

Speaker Philippe Timmermans

Congress : Heart Failure 2019

  • Topic : valvular, myocardial, pericardial, pulmonary, congenital heart disease
  • Sub-topic : Myocarditis
  • Session type : Poster Session
  • FP Number : P1811

Authors : PHT Timmermans (Hasselt,BE), A Barradas-Pires (London,GB), O Ali (Detroit,US), M Henkens (Maastricht,NL), S Heymans (Maastricht,NL), K Negishi (Hobart,AU)

PHT Timmermans1 , A Barradas-Pires2 , O Ali3 , M Henkens4 , S Heymans4 , K Negishi5 , 1Jessa Hospital, Rehabilitation and Health Centre, Heart Centre - Hasselt - Belgium , 2Royal Brompton Hospital, cardiology - London - United Kingdom of Great Britain & Northern Ireland , 3Wayne State University, cardiology - Detroit - United States of America , 4Cardiovascular Research Institute Maastricht (CARIM) - Maastricht - Netherlands (The) , 5Menzies Research Institute - Hobart - Australia ,



Combination immune suppression with prednisolone and azathioprine (IPA) is used to treat heart failure due to chronic non-fulmintant non-viral myocarditis.  However, there has been inconsistency in the effects of immunosuppression treatment. 
A systematic review and meta-analysis of trials using (IPA) to treat HF refractory to OMT caused by chronic non-fulminant virus negative or "autoimmune" myocarditis was conducted to demonstrate the effect on LV EF and the combined clinical endpoint of cardiovascular mortality and/or HTx-free survival. 

Methods and results 
All trials with using IPA versus OMT were searched using OVID Medline and, following the PRISMA guidelines. Missing clinical outcome data was retrieved after contacting the corresponding authors. All data was reviewed and analysed using  and standard meta-analysis methods. A random effect model was used to pool the effect sizes.  
A total of 4 trials were identified. Two were published RCT, one was an aborted RCT without publication but randomised and treated 20 patients and one was a published registry with a corresponding control group, resulting in a total of 369 patients.
IPA on top of OMT did not improve LVEF (mean difference 9.9% [95% confidence interval -1.8, 21.7]). Because of the significant heterogeneity (I296.8%, p<0.001) we performed  a subanalysis of this result. First, the studies were divided by whether RCT or not, where I2values remained similar (96.9%). Then, they were sub-grouped by whether published or not, which did not reduce I2-values but the pooled estimates of the change in LVEF became significantly positive with 14% [1.4, 26.6]. 

A trend towards a benefit in the combined endpoint of cardiovascular mortality and/or heart transplantation-free survival was observed with the intervention but did not reach clinical significance (risk ratio 0.34 [0.08, 1.51]). Because of a moderate heterogeneity (I2= 60%), we again performed a subgroup analyses. When categorised by RCT or not, heterogeneity significantly dropped close to low level (32%) with no difference in the pooled RR of the RCTs. Sub-grouping by publication status increased heterogeneity to almost high category (I2=72.9%). 

At the moment, there is insufficient evidence supporting functional and prognostic benefits of IPA added to OMT in virus negative inflammatory positive cardiomyopathy.  
There is a potential positive effect on both LV EF and the combined endpoint of cardiovascular mortality or HTx-free survival. Significant heterogeneity exist among individual publications regarding diagnosis, dose regime, duration of therapy, study design and quality of the data. More research is needed to elucidate the exact impact of this treatment. Further adequate-powered well-designed prospective RCTs should be warranted to explore the potential effects of adding immunosuppressive therapy to OMT.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are